BRIEF-Shanghai Fosun Pharmaceutical Group's Unit Signs Licensing Deal With Amberstone

2

Sept 23 (Reuters) – Shanghai Fosun Pharmaceutical Group Co Ltd: * SAYS UNIT SIGNED LICENSING DEAL WITH AMBERSTONE FOR TCE PRODUCTS * SAYS UNIT TO PAY AMBERSTONE UP TO $236.16 MLN IN UPFRONT, R&D FEES,

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)